Senior Immunologist – Cambridge

Jim Gleeson is recruiting for a Senior Immunologist to join a major global biotechnology company on a permanent basis at their offices in the East Anglia

As a key member of the R&D team you will be expected to provide expertise in immunology and toxicology within non-clinical safety assessment and ensuring appropriate strategies and toxicological interpretations are provided to meet business objectives.

This role requires someone with a strong immunology background and a PhD in a relevant subject.

Click here for more information or to apply for this position >

 

Posted in Job News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Regional Medical Liaison – UK

CK Clinical is recruiting for a Regional Medical Liaison to join a company in the pharmaceutical industry in a contract role in the South of England.

The main purpose will be to support a large scale phase 3 clinical trial of a key pipeline molecule in a cardiology/lipidology therapeutic area to help deliver recruitment targets.

To be considered for this role you will have a scientific degree a minimum (preferably a higher degree) and have excellent knowledge of the drug development process.

 

Read the full job description here

Posted in Job News, NewsTagged in , , , , , , , , , , , , , , , , , , , ,

Eli Lilly Drugs Trial Success

Eli Lilly has had success in its Phase III trial for necitumumab, the company’s successor to Erbitux.

The study produced promising overall survival data for non-small cell lung cancer which means that a regulatory filing has been slated for 2014. The drug, when combined with others, allowed for a much better survival rate when compared to chemotherapy alone for people with stage IV metastatic squamous non-small cell lung cancer.

The results were a surprise, coming off the back of fears that the drug caused blood clots in some patients. However, instances have become less frequent. If approved, necitumumab may become the first drug to treat squamous lung cancer.

Looking for a job in the clinical sector? Start by clicking here.

     

987zzz321
zp8497586rq
Posted in Featured Jobs, NewsTagged in , , , , , , , , , , , , , ,

Amgen Cites CK as Top Job Supplier

Leading biotechnology company Amgen has recognised CK Clinical as its top supplier for jobs in the UK.

The CK Clinical team were ranked first for jobs filled in the UK for the first quarter of 2013, a fantastic achievement by our team. To be recognised by a company such as Amgen as their best job supplier is excellent, and continues to demonstrate CK Clinical’s ongoing determination to provide the best possible service we can to clients and candidates alike.

Amgen has been a leading biotechnology company since 1980 and has helped change the practice of medicine to the benefit of millions around the world fighting various diseases, from cancer to bone and kidney disease, amongst others. Amgen launched biotechnology’s first blockbuster treatments and is still committed to helping millions of people fight serious illness.

Search for our biotechnology jobs here

CK Clinical - Contract Recruitment for Pharma, Biotech and CRO

jfdghjhthit45
zp8497586rq
Posted in company news, Industry News, NewsTagged in , , , , , , , , , ,

CK Clinical Celebrate the Opening of London Office

CK Clinical, is today celebrating the opening of our new London office. With an already thriving office based in Stevenage Hertfordshire, our new London office will be the hub of our expanding recruitment operations across Europe.

This is an extremely exciting time for CK, as Priya Priya Mukherjee, European Operations Manager explains, “I am delighted to be part of the new European expansion and looking forward to taking CK Clinical to new heights across the European Pharmaceutical market.

Being based at our new central London location means we have easy access to London City Airport and Heathrow, enabling us to continue the great service we offer and meet our clients and candidates when required. We are all looking forward to the coming months and settling into our new place of work.”

 

The new London office will be home to a number of CK Clinical’s specialist Clinical Recruitment Consultants including:

 

  • Priya Mukherjee - European Operations Manager at CK ClinicalPriya Mukherjee, European Operations Manager

Priya is heading up CK Clinical’s European recruitment operations and will also be focusing on Biometrics recruitment across Europe.

 

 

 

 

 

  • Moin Din - Senior Recruitment Consultant at CK ClinicalMoin Din, Senior Recruitment Consultant

Moin specialises in recruiting medically qualified professionals within the pharmaceutical industry across the UK and Europe.

 

 

 

 

 

  • Mylene Paumier - Consultant at CK ClinicalMylene Paumier, Recruitment Consultant

Mylene specialises in recruiting for Biometrics professionals within the pharmaceutical industry across the UK and Europe.

 

 

 

 

 

  • Hendre Moolman - Senior Consultant at CK ClinicalHendre Moolman, Senior Recruitment Consultant

Hendre Moolman specialises in recruiting for Pharmacovigilance, Drug Safety, Medical Information and Medical Affairs professionals within the pharmaceutical industry across the UK and Europe.

 

 

 

The address of CK Clinical’s new London office is as follows:

CK Clinical London Office in HammersmithCrown House

72 Hammersmith Road

Hammersmith

London

W14 8TH

Tel: +44 (0)207 470 5670

 

Posted in General, NewsTagged in , , , , , , , , , , , , , , , , , , , , , ,

EU patent ban announced on stem cell research

As reported by the BBC, The European Court of Justice has banned the issuing of patents for embryonic stem cell research.

The research has been banned on ethical grounds as it involves the destruction of human embryos.

Stem cell research involves extracting human embryonic stem cells from surplus vitro fertilised eggs donated after fertility treatment. The cells are then modified and injected into patients. These cells are a useful tool for repairing and regenerating diseased organs and tissues.

The European Court has stated that “scientific research entailing the use of human embryos cannot access the protection of patent law” and that it is unethical to profit from what it sees as the fundamentals of human life.

The case was originally raised by Greenpeace against scientist, Oliver Brustle, who was investigating the use of stem cells to treat neurological diseases such as Parkinson’s.

So, whilst there are no restrictions on human embryonic stem cell research in Europe, it will now be extremely difficult to get patent approval for any new discoveries that are made as a result of this research.

The ruling is a real blow to the commercial development of such products within the European Union. The ruling effectively means that any stem cell research technique invented by scientists working in the EU can now be easily and legally copied by rival scientists.

Lastly, there is also a fear that this type of research could be pushed elsewhere as Pharmaceutical companies in the EU will be less inclined to seek involvement as they are now unable to safeguard their investment.

Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.

Posted in Featured Jobs, NewsTagged in , , , , , , , , , , , , , , , , , , , ,

FDA questions effectiveness of Parkinson’s drug

As reported by Reuters, the Food and Drug Administration (FDA) is questioning the effectiveness of Teva Pharmaceutical Industries drug Azilect.

Azilect already has approval by the FDA to treat symptoms of the neurological disorder (such as shaking, stiffness, impaired balance). However, Teva are now seeking an extension of Azilect’s label. However, it is being scrutinized by the FDA as they question it’s effectiveness in slowing down the progression of the disease.

Scepticism regarding the drug stems from results from Teva’s latest trial – the disease appeared to deteriorate more slowly in patients who started taking the drug early in the progression of the disease, rather than later. However, whilst the 1mg dose slowed progression, the 2mg dose did not. This has brought questions about the trial results.

Looking for a new role in the pharmaceutical industry? Click here to search our current pharmaceutical jobs now.

Posted in NewsTagged in , , , , , , , , , , , , , , , , , ,

Amgen’s Bone Drug is Granted Two New Approvals

As reported by Pharma Times, Amgen’s new bone drug, Prolia has received two new indications by the US Food and Drug Administration:

  1. Prolia can how be used to help increase bone mass in women who are at high risk or fracture
  2. The drug has now been approved to increase bone mass in men at high risk of fracture who are receiving ADT for non-metastic prostate cancer.

The drug first received approval in the US in 2010  for the treatment of osteoporosis in post-menopausal women who are at high risk of fractures.

Are you looking for a new position in Drug Development? Click here to search our current roles online now.

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , ,

Innovative New Prostate Cancer Drug Developed

As reported by the BBC, a new treatment for the advanced and aggressive form of prostate cancer has been developed by Scientists at Queen’s University.

The drug will now be tested in a second phase, combines chemotherapy treatments with two doses of a radioactive chemical.

Speaking of the new treatment, Consultant and Senior Lecturer in Clinical Oncology, Dr O’Sullivan stated,

“This is a significant development in the fight against prostate cancer. While this combination treatment still has to go to phase two of trials, to know that this combination is safe and feasible as a treatment is a huge step forward.”

Looking for a job in the Pharmaceutical Industry? Click here to search our current jobs online now.

Posted in Featured Jobs, NewsTagged in , , , , , , , , , , , , , , , , ,

Director of Health Outcomes Job in London

Jonathan Hart-Smith at CK Clinical is looking for a Director of Health Outcomes to join his client based in London.

The job:

As Director of Health Outcomes you will play a pivotal role in guiding the organisation, providing a strategic insight and understanding of theirs client’s and stakeholders needs.

As Director of Health Outcomes you will also be responsible for developing important relationships with instrument authors and key opinion leaders and make recommendations on instrument selection and validation. You will support the Sales and Operations streams and participate in bed defences.

In addition, you will represent the company at scientific conferences, webinars and be recognized as an authority in the industry.

 

The ideal candidate:

To be considered for this Director of Health Outcomes position, you will possess comprehensive knowledge of the regulatory requirements in the EU and US for patient reported outcomes. In addition, this role demands candidates with a broad and diverse understanding of many different therapeutic areas.

How to apply:

For more information or to apply for this Health Outcomes Director role, please contact Jonathan on 01438 743 047 or email jhartsmith@ckclinical.co.uk.

Posted in Featured Jobs, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , , , ,